Literature DB >> 26066297

Association of STAT4 rs7574865 polymorphism with susceptibility to inflammatory bowel disease: A systematic review and meta-analysis.

Qi-Fei Liu1, Yi Li1, Qi-Hong Zhao1, Zheng-Yu Wang1, Shuang Hu1, Chao-Qun Yang1, Kui Ye1, Li Li2.   

Abstract

OBJECTIVE: Association of Signal transducers and activators of transcription-4 (STAT4) gene polymorphism with susceptibility to inflammatory bowel disease have been investigated in a number of epidemiological studies, but the results are inclusive. The aim of this meta-analysis was to more precisely estimate the relationship.
METHODS: The databases of Pubmed and CBM updated to October, 2014 were retrieved. Random- or fixed-effect model was used to estimate odd radio (OR) and corresponding 95% confidence interval (95%CI) on the basis of heterogeneity.
RESULTS: Seven articles containing 2196 Crohn's disease (CD) cases, 1588 ulcerative colitis (UC) cases and 4126 controls were identified. We detected a significant association between STAT4 rs7574865 polymorphism and IBD susceptibility in overall population (GG vs. GT+TT, OR=0.855, 95% CI=0.760-0.962, P=0.009), but not in Caucasian and Asian population, respectively. No association was detected between rs7574865 polymorphism and CD susceptibility in overall, Asian and Caucasian population, respectively. Interestingly, a significant association was detected between rs7574865 with UC susceptibility in overall population (G vs. T, OR=0.881, 95% CI=0.798-0.972, P=0.012; GG vs. GT+TT, OR=0.788, 95% CI=0.679-0.914, P=0.002; GG vs. TT, OR=0.683, 95% CI=0.498-0.937, P=0.018) and Caucasians (GG vs. GT+TT, OR=0.833, 95% CI=0.701-0.990, P=0.038; GG+GT vs. TT, OR=0.667, 95% CI=0.456-0.975, P=0.037; GG vs. TT, OR=0.636, 95% CI=0.433-0.934, P=0.021), respectively, and a possible association was found in Asian population (GG vs. GT+TT, OR=0.709, 95% CI=0.503-0.998, P=0.049).
CONCLUSIONS: STAT4 rs7574865 gene is IBD risk factor, and this gene polymorphism is associated with UC susceptibility, especially in Caucasians. To confirm these findings, further studies with more sample size are required for a definitive conclusion.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26066297     DOI: 10.1016/j.clinre.2015.04.002

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  6 in total

1.  Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.

Authors:  Sanjay S Shete; Maria E Suarez-Almazor; Noha Abdel-Wahab; Adi Diab; Robert K Yu; Andrew Futreal; Lindsey A Criswell; Jean H Tayar; Ramona Dadu; Vickie Shannon
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

Review 2.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

3.  STAT4 gene polymorphism in patients after renal allograft transplantation.

Authors:  Ewa Dąbrowska-Żamojcin; Violetta Dziedziejko; Krzysztof Safranow; Leszek Domański; Sylwia Słuczanowska-Głabowska; Andrzej Pawlik
Journal:  Cent Eur J Immunol       Date:  2016-10-25       Impact factor: 2.085

4.  Polymorphisms of the STAT4 gene in the pathogenesis of tuberculosis.

Authors:  Shouquan Wu; Minggui Wang; Yu Wang; Miaomiao Zhang; Jian-Qing He
Journal:  Biosci Rep       Date:  2018-08-29       Impact factor: 3.840

Review 5.  Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.

Authors:  Friederike Cordes; Dirk Foell; John Nik Ding; Georg Varga; Dominik Bettenworth
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

Review 6.  Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer.

Authors:  Sebastian Zundler; Markus F Neurath
Journal:  Vaccines (Basel)       Date:  2016-02-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.